NULL
New Jersey

CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week

MONMOUTH JUNCTION, , Nov. 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around…
Continue Reading »
New Jersey

Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st

BRIDGEWATER, , Nov. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal…
Continue Reading »